Definition and management of oligoprogression during treatment with TKI inhibitors
Optimal genome profiling for re-biopsy of TKI resistant tumour
Date
08 Oct 2016Session
Definition and management of oligoprogression during treatment with TKI inhibitorsPresenters
Keith KerrAuthors
K. KerrAuthor affiliations
- Aberdeen Royal Infirmary, AB25 2ZN - Aberdeen/GB
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Practicalities and risks of biopsy
Presenter: Josephine Barry
Session: Definition and management of oligoprogression during treatment with TKI inhibitors
Resources:
Slides
The perspective of the oncologist
Presenter: Egbert Smit
Session: Definition and management of oligoprogression during treatment with TKI inhibitors
Resources:
Slides